GlassScriptPhysician profile
Michael Hauk
NPI 1801389580
$10,818.34
in general payments reported to CMS, 2019-2025
23 companies · $2,340 in 2025
The $2,340 reported for 2025 was more than what 75% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $781 · 2022: $2,305 · 2023: $2,724 · 2024: $2,543 · 2025: $2,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,070 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $500 · Consulting Fee: $28.95 · Education: $8.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,069.77 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $500.00 |
| Consulting Fee | $28.95 |
| Education | $8.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,366.43 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,978.97 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,809.64 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Pharmaceuticals, INC. | $1,000.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $970.46 | 2021-2025 | Dupixent |
| Amgen INC. | $416.35 | 2022-2025 | Tezspire |
| Aerin Medical INC. | $362.07 | 2022-2024 | |
| Genentech USA, INC. | $280.92 | 2023-2024 | Xolair |
| Csl Behring | $252.87 | 2022-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $227.11 | 2023-2025 | |
| Pfizer INC. | $202.97 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.49 | 2021-2024 | Takhzyro, Cuvitru, Eohilia |
| Lilly USA, LLC | $144.53 | 2024-2025 | Ebglyss, Taltz |
| Optinose US, INC. | $133.43 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $118.16 | 2023 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $54.21 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $49.51 | 2023-2024 | Ryaltris |
| Abbvie INC. | $32.16 | 2024 | |
| Adma Biomanufacturing LLC | $28.95 | 2024 | |
| Incyte Corporation | $27.14 | 2025 | Opzelura |
| Alk-Abello, INC | $22.77 | 2023 | Ragwitek, Odactra, Grastek |
| Galderma Laboratories, L.P. | $22.20 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hauk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.